Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: Exploratory analysis from 12,076 patients

Oncotarget

Volumn 8, Issue 31, 2017, Pages 50804-50813

  Alshalalfa, Mohammed ^a   Verhaegh, Gerald W ^b,c   Gibb, Ewan A ^a   Santiago Jiménez, Maria ^a   Erho, Nicholas ^a   Jordan, Jennifer ^a   Yousefi, Kasra ^a   Lam, Lucia L C ^a   Kolisnik, Tyler ^a   Chelissery, Jijumon ^a   Seiler, Roland ^a,d   Ross, Ashley E ^e   Karnes, R Jeffrey ^f   Schaeffer, Edward M ^g   Lotan, Tamara T ^h   Den, Robert B ⁱ   Freedland, Stephen J ^j   Davicioni, Elai ^a   Klein, Eric A ^k   Schalken, Jack A ^b,c  

^a GenomeDx Biosciences Inc   (Canada)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f MAYO CLINIC   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

Initial biopsy; PCA3; Prognosis; Prostate cancer; Under diagnosis

Indexed keywords

TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL OUTCOME; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; FALSE NEGATIVE RESULT; GENE; GENE EXPRESSION; GENE LOCATION; GENETIC ASSOCIATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PCA3 GENE; PREVALENCE; PROSTATE BIOPSY; PROSTATE TUMOR; PROSTATECTOMY; SENSITIVITY ANALYSIS; SURVIVAL RATE; TUMOR DIFFERENTIATION;

EID: 85026675084     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15133     Document Type: Article

References (32)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108. doi:10.3322/caac.21262
2. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013; 8:e66855. doi:10.1371/journal.pone.0066855
3. Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 2014; 15:1469-80. doi:10.1016/S1470-2045(14)71113-1
4. Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 2013; 45:1392-8. doi:10.1038/ng.2771
5. White N, Zhao S, Zhang J, Rozycki E, Dang H, McFadden S, Eteleeb AM, Alshalalfa M, Vergara IA, Erho N, Arbeit JM, Karnes RJ, Den RB, et al. Multi-institutional analysis shows that low PCAT-14 expression associates with poor outcomes in prostate cancer. Eur Urol. 2017; 71:257-66
6. Loeb S, Partin AW. Review of the literature: PCA3 for prostate cancer risk assessment and prognostication. Rev Urol. 2011; 13:e191-5
7. Salagierski M, Schalken JA. PCA3 and TMPRSS2-ERG: promising biomarkers in prostate cancer diagnosis. Cancers (Basel). 2010; 2:1432-40. doi:10.3390/cancers2031432
8. Bussemakers MJG, Van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HFM, Schalken JA, Debruyne FM, Ru N, Isaacs WB. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59:5975-9. doi:10.1038/ncb2161
9. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA. DD3PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002; 62:2695-8
10. Popa I, Fradet Y, Beaudry G, Hovington H, Beaudry G, Têtu B. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol. 2007; 20:1121-7. doi:10.1038/modpathol.3800963
11. Haese A, de la Taille A, van Poppel, H Marberger M, Stenzl A, Mulders P, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008; 54:1081-8
12. Marks LS, Fradet Y, Lim Deras I, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007; 69:532-5. doi:10.1016/j.urology.2006.12.014
13. Hessels D, Klein Gunnewiek J, van Oort I, Karthaus H, van Leenders G, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003; 44:8-15
14. Elshafei A, Chevli KK, Moussa AS, Kara O, Chueh SC, Walter P, Hatem A, Gao T, Jones JS, Duff M. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy. Prostate. 2015; 75:1951-7. doi:10.1002/pros.23096
15. Roobol MJ, Schröder FH, van Leenders GL, Hessels D, Van Den Bergh RCN, Wolters T, van Leeuwen PJ. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (=100). Eur Urol. 2010; 58:893-9. doi:10.1016/j. eururo.2010.09.030
16. Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, Chan DW, Lotan Y, Kibel AS, Busby JE, Bidair M, Lin DW, Taneja SS. Can urinary PCA3 Supplement PSA in the early detection of prostate cancer? J Clin Oncol. 2014; 32:4066-72. doi:10.1200/JCO.2013.52.8505
17. Fenstermaker M, Mendhiratta N, Bjurlin MA, Meng X, Rosenkrantz AB, Huang R, Deng FM, Zhou M, Huang WC, Lepor H, Taneja SS. Risk stratification by urinary PCA3 testing prior to MRI-US fusion-targeted prostate biopsy among men with no previous history of biopsy. Urology. 2017; 99:174-9
18. Warrick JI, Tomlins SA, Carskadon SL, Young AM, Siddiqui J, Wei JT, Chinnaiyan AM, Kunju LP, Palanisamy N. Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization-a correlative study with urine PCA3 and TMPRSS2-ERG. Mod Pathol. 2014; 27:609-20. doi:10.1038/modpathol.2013.169
19. Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, et al. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol. 2015; 68:555-67. doi:10.1016/j.eururo.2015.04.033
20. Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humphreys EB, et al. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate-and high-risk men. Eur Urol. 2016; 69:157-65. doi:10.1016/j.eururo.2015
21. Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2014; 89:1038-46. doi:10.1016/j.ijrobp.2014.04.052
22. Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, Li J, Kattan MW, Magi-Galluzzi C, Davicioni E. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in nodenegative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol. 2015; 67:778-86. doi:10.1016/j.eururo.2014.10.036
23. Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk Patient population. J Urol. 2013; 190:2047-53. doi:10.1016/j.juro.2013.06.017
24. Ruffion A, Devonec M, Champetier D, Decaussin-Petrucci M, Rodriguez-Lafrasse C, Paparel P, Perrin P, Vlaeminck-Guillem V. PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy. Int J Mol Sci. 2013; 14:17767-80. doi:10.3390/ijms140917767
25. Lemos AEG, Ferreira LB, Batoreu NM, de Freitas PP, Bonamino MH, Gimba ERP. PCA3 long noncoding RNA modulates the expression of key cancer-related genes in LNCaP prostate cancer cells. Tumor Biol. 2016; 37:11339-48 doi:10.1007/s13277-016-5012-3
26. Ferreira L, Palumbo A, de Mello K, Sternberg C, Caetano M, de Oliveira F, Neves AF, Nasciutti LE, Goulart LR, Gimba ER. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer. 2012; 12:507
27. Salagierski M, Verhaegh GW, Jannink SA, Smit FP, Hessels D, Schalken JA. Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. Prostate. 2010; 70:70-8. doi:10.1002/pros.21040
28. Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, Leyten GH, de Reijke TM, Vergunst H, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol. 2016; 70:740-48. doi:10.1016/j.eururo.2016.04.012
29. Freedland SJ, Choeurng V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam LL, Buerki C, Ra S, Robbins B, Trabulsi EJ, Shah NL, Abdollah F, et al. Utilization of a genomic classifier for prediction of metastasis following salvage radiation therapy after radical prostatectomy. Eur Urol. 2016; 70:588-96. doi:10.1016/j.eururo.2016
30. Glass AG, Leo MC, Haddad Z, Yousefi K, du Plessis M, Chen C, Choeurng V, Abdollah F, Robbins B, Ra S, Richert-Boe KE, Buerki C, Pearson K, et al. Validation of a genomic classifier for predicting post-prostatectomy recurrence in a community based health care setting. J Urol. 2015; 195:1748-53. doi:10.1016/j.juro.2015.11.044
31. Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, Dicker AP, Lallas CD, Gomella LG, Davicioni E, Karnes RJ. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015; 33:944-51. doi:10.1200/JCO.2014.59.0026
32. Klein, EA, Cooperberg, MR, Magi-Galluzzi, C, Simko, JP, Falzarano, SM, Maddala, T, Chan, JM, Li, J, Cowan, JE, Tsiatis, AC, Cherbavaz, DB, Pelham, RJ, Tenggara-Hunter, I, et al. M. PR. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014; 66:550-60